Hamburg - Delayed Quote • EUR Mesoblast Ltd (LWB.HM) Follow Compare 1.8400 +0.0700 +(3.95%) As of 5:25:07 PM GMT+1. Market Open. Comparisons Indicators Technicals Corporate Events Line Candle Baseline Mountain Bar Step Baseline Delta HLC Wave Scatterplot Histogram Range Channel Colored Line Colored Mountain Colored Step Colored Bar Colored HLC Volume Candle Hollow Candle Step Mountain Verex Line Vertex Step Vertex Mountain Vertex Baseline Delta Draw List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Loading Chart for LWB.HM 1D 5D 4.55% 1M 7.60% 3M 135.90% 6M 214.53% YTD 7.60% 1Y 1,087.10% 5Y 3.37% All 127.55% Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours 1 day 1 week 1 month 3 months Recent News: LWB.HM View More All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Is Mesoblast Limited (MESO) One of the Best ASX Stocks to Buy According to Hedge Funds? Ryoncil® Commercial Launch Update and Product Pipeline Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2024 Why Mesoblast (MESO) Is Among the Best Australian Stocks to Buy Now? 3 ASX Growth Stocks With High Insider Ownership Seeing Up To 55% Earnings Growth Bullish Mesoblast Insiders Loaded Up On US$145.4m Of Stock MESO Stock Surges 80% in a Month After FDA Approval of GVHD Drug Exploring 3 High Growth Tech Stocks In Australia What Awaits These 4 Biotech Stocks That More Than Doubled in 2024 Top-Notch Biotech Mesoblast Skyrockets On Immune Condition Approval MESO Stock Up as FDA Approves Ryoncil for Graft Versus Host Disease